(Alliance News) - European equities were higher at midday on Monday, bouncing back from a lower start, as investors took a warning from a business poll that showed Germany is on "brink of recession" in their stride. Read More
(Alliance News) - AstraZeneca PLC on Monday said it won two recommendations for approval in the EU and one priority review in the US. Read More
(Alliance News) - A UK government led by Rishi Sunak will be good news for pharmaceutical firms, while Liz Truss could lift retail share prices with her plan to cut personal income taxes, analysts at Brewin Dolphin said on Thursday, after the race to Number 10 was whittled down to two. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said a breast cancer drug developed with Tokyo-based partner Daiichi Sankyo Co Ltd has been approved in the European Union. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZeneca PLC's savolitinib in combination with Astra's osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday: Read More
(Alliance News) - Stock prices in London are seen opening higher on Tuesday, continuing a somewhat confident start to the third quarter for equities, despite inflationary and recessionary fears showing little sign of fading. Read More
(Alliance News) - Stocks in London opened lower on Friday as investors continued to fret over prospects of a recession as central banks raise interest rates. Read More
(Alliance News) - Oxford BioMedica PLC on Friday said it has signed a new three year agreement with AstraZeneca PLC, which will facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine. Read More
(Alliance News) - Stock prices in London are seen opening lower on Friday following another sell-off on Wall Street fuelled by recession fears, while focus will be on a slew of manufacturing PMI readings later in the day. Read More
(Alliance News) - AstraZeneca PLC on Thursday said its antibody Imfinzi, when used with chemotherapy, significantly improved responses in a form of cell lung cancer. Read More
Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going." Read More
(Alliance News) - Stock prices in London opened higher on Monday amid hopes of less aggressive monetary policy tightening by central banks, while Biffa shares fell after a delay to the publication of its annual results. Read More
(Alliance News) - AstraZeneca PLC said on Monday that its breast cancer treatments, Lynparza and Enhertu, have been recommended for approval in the EU. Read More
(Alliance News) - Stock prices in London are seen opening higher on Monday following a strong close in the US on Friday and a rally across Asian markets, amid gatherings of world leaders and central bankers at separate meetings in Europe this week. Read More
(Alliance News) - AstraZeneca PLC on Thursday reported strong results from phase III clinical trials for ALXN1840. Read More
(Alliance News) - Merck & Co Inc on Tuesday said its Lynparza drug, developed alongside AstraZeneca PLC, improved survival rates for some sufferers of prostate cancer. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said eplontersen, its candidate for a form of hereditary polyneuropathy, demonstrated significant positive results in a phase 3 trial interim analysis. Read More